Company Appoints Distinguished UCLA Oncology Surgeon to SAB, Enhancing Board’s Expertise in Surgical Oncology and Translational Oncology Research Aimed at Improving Multidisciplinary Treatment StrategiesMOUNTAIN VIEW, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced the appointment of renown ...